Resmed (RMD) Equity Average (2010 - 2026)

Resmed has reported Equity Average for 17 years, with the latest figure at $6.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 18.65% year-over-year to $6.4 billion; the trailing twelve-month figure through Mar 2026 stood at $6.4 billion (up 18.65% YoY), and the FY2025 full-year result was $5.4 billion, up 20.44% from the prior year.
• Equity Average for Q1 2026 stood at $6.4 billion, up from $6.2 billion in the prior quarter.
• The five-year high for Equity Average was $6.4 billion in Q1 2026, with the low at $3.2 billion in Q1 2022.
• Historically, Equity Average has averaged $4.7 billion across 5 years, with a median of $4.6 billion in 2024.
• Annual changes were most pronounced in 2022 — Equity Average advanced 14.92% — and 2023, when it rose 23.35%.
• Resmed's Equity Average stood at $3.6 billion in 2022, then advanced by 21.77% to $4.4 billion in 2023, then advanced by 19.65% to $5.2 billion in 2024, then climbed by 19.09% to $6.2 billion in 2025, then gained by 2.98% to $6.4 billion in 2026.
• The last three Equity Average figures came in at $6.4 billion (Q1 2026), $6.2 billion (Q4 2025), and $6.0 billion (Q3 2025), per Business Quant data.